The New England journal of medicine
-
Comment Letter
Clonal Hematopoiesis Leading to AITL and NPM1-Mutated AML.
-
Randomized Controlled Trial Multicenter Study
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Unresectable locally advanced or metastatic triple-negative (hormone-receptor-negative and human epidermal growth factor receptor 2 [HER2]-negative) breast cancer is an aggressive disease with poor outcomes. Nanoparticle albumin-bound (nab)-paclitaxel may enhance the anticancer activity of atezolizumab. ⋯ Atezolizumab plus nab-paclitaxel prolonged progression-free survival among patients with metastatic triple-negative breast cancer in both the intention-to-treat population and the PD-L1-positive subgroup. Adverse events were consistent with the known safety profiles of each agent. (Funded by F. Hoffmann-La Roche/Genentech; IMpassion130 ClinicalTrials.gov number, NCT02425891 .).